Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma

Anagha Deshpande, Yucai Wang, Javier Munoz, Preetesh Jain

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

In July 2020, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (BA), the first anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed/refractory mantle cell lymphoma (MCL). The pivotal ZUMA-2 trial led to the approval of BA in patients who experienced relapsed disease on prior therapies (chemotherapy and/or Bruton tyrosine kinase [BTK] inhibitors). The FDA approval of BA was based on excellent responses with this therapy in highly refractory patients with MCL, who conventionally had poor outcomes. Longer follow-up data from the ZUMA-2 study have been presented at recent international meetings. As is common with other CAR T-cell therapies in lymphomas, the main toxicities of BA therapy included cytokine release syndrome (CRS), infections, cytopenias and CAR-associated neurotoxicity. In this review, we provide a summary of the data in the development of BA and its impact on MCL patient survival and future directions.

Original languageEnglish (US)
Pages (from-to)283-298
Number of pages16
JournalDrugs of Today
Volume58
Issue number6
DOIs
StatePublished - Jun 2022

Keywords

  • Anti-CD19 therapies
  • Brexucabtagene autoleucel
  • Cancer immunotherapy
  • Chimeric antigen receptor (CAR) T-cell therapy
  • Hematologic malignancies
  • Mantle cell lymphoma
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma'. Together they form a unique fingerprint.

Cite this